Skip to main content
Clinic BPC-157 A device-clean research console on BPC-157 — the three small human pilots read first, the deep animal-recovery literature beneath them, and where compounded access actually stands.

STUDIES / FDA RECORDS / SOURCE NUMBERS

How can you check a BPC-157 claim?

Match the small number after a BPC-157 claim with the same number in the list below.

Return to the findingsReview the pharmacy facts

Each source number opens the paper or FDA record

How can you check a claim? Match its small number to the list below. One group has BPC-157 tests in people, rats, and cells. Another has the FDA records used for BPC-157 legal status. The paper list includes the three short human studies and newer animal work.

A PubMed link opens a public library record for a medical paper. DOI means digital object identifier. It is a lasting label for one paper, and you can expect its link to keep leading there even when a journal later changes the paper’s own web address for you. Either kind of link can help you find the full source.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
  3. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
  4. Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1037. ↗
  5. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. ↗
  6. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  7. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. ↗
  8. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024. ↗
  9. Klicek R, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats. J Pharmacol Sci. 2008;108(1):7-17. ↗
  10. Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System. Pharmaceuticals (Basel). 2026;19(1):145. ↗
  11. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Acute Pancreatitis. Medicina (Kaunas). 2025;61(2):291. ↗
  12. Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Effect Following Intoxications. Pharmaceuticals (Basel). 2025;18(6):928. ↗
  13. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA.gov (verified 2026-05-29). ↗
  14. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (BPC-157 entry, effective 2023-09-29). FDA.gov (verified 2026-05-29). ↗
  15. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (guidance finalized January 2025). FDA.gov (verified 2026-05-29). ↗
  16. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (BPC-157 listed as a substance being considered for the 503A Bulks List). FDA.gov (verified 2026-05-29). ↗
  17. Author group (2025) BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025. 18:1450. ↗
  18. Tohyama Y, et al. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyltryptophan autoradiographic measurements. Life Sci. 2004. 76:345-357. ↗
  19. Boban Blagaic A, et al. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol. 2005. 512:173-179. ↗
  20. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. 19:19066-19077. ↗